Abstract
Delay in diagnosis of cardiac involvement with amyloidosis (CA) is common predominantly due to nonspecific symptoms and indistinct patterns on non-invasive cardiac testing. An effective serum biomarker may improve early diagnosis of CA. Consecutive patients with light chain (AL) or transthyretin (
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
